340 related articles for article (PubMed ID: 25990612)
1. Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging.
Muralidhar V; Dinh KT; Mahal BA; Ziehr DR; Chen YW; Viswanathan VB; Nezolosky MD; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Trinh QD; Nguyen PL
Urol Oncol; 2015 Jul; 33(7):330.e19-25. PubMed ID: 25990612
[TBL] [Abstract][Full Text] [Related]
2. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
3. Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy.
Tsumura H; Ishiyama H; Tabata KI; Katsumata H; Kobayashi M; Ikeda M; Kurosaka S; Fujita T; Kitano M; Satoh T; Yanagisawa N; Hayakawa K; Iwamura M
Prostate; 2017 Nov; 77(15):1520-1527. PubMed ID: 28905446
[TBL] [Abstract][Full Text] [Related]
4. 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer.
Mitchell CR; Boorjian SA; Umbreit EC; Rangel LJ; Carlson RE; Karnes RJ
BJU Int; 2012 Dec; 110(11):1709-13. PubMed ID: 22934913
[TBL] [Abstract][Full Text] [Related]
5. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
6. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.
Muralidhar V; Chen MH; Reznor G; Moran BJ; Braccioforte MH; Beard CJ; Feng FY; Hoffman KE; Choueiri TK; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):828-35. PubMed ID: 26530751
[TBL] [Abstract][Full Text] [Related]
7. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
8. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
[TBL] [Abstract][Full Text] [Related]
9. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.
Yang DD; Muralidhar V; Nguyen PL; Buzurovic I; Martin NE; Mouw KW; Devlin PM; Trinh QD; Orio PF; King MT
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):904-911. PubMed ID: 29063853
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract][Full Text] [Related]
11. Commentary on "initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer." Aizer AA, Chen MH, Hattangadi J, D'Amico AV. Harvard Radiation Oncology program, Boston, MA.: BJU Int 2013. doi: 10.1111/j.1464-410X.2012.11789.x. [Epub ahead of print].
Ritter MA
Urol Oncol; 2014 Feb; 32(2):208-9. PubMed ID: 24445289
[TBL] [Abstract][Full Text] [Related]
12. Age, Comorbidity, and the Risk of Prostate Cancer-Specific Mortality in Men With Biopsy Gleason Score 4+3: Implications on Patient Selection for Multiparametric MRI.
Chandra RA; Chen MH; Zhang D; Loffredo M; D'Amico AV
Clin Genitourin Cancer; 2015 Aug; 13(4):400-405. PubMed ID: 25862319
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study.
Dell'Oglio P; Abou-Haidar H; Leyh-Bannurah SR; Tian Z; Larcher A; Gandaglia G; Fossati N; Shariat SF; Capitanio U; Briganti A; Montorsi F; Graefen M; Saad F; Karakiewicz PI
Eur Urol; 2016 Sep; 70(3):429-35. PubMed ID: 26951945
[TBL] [Abstract][Full Text] [Related]
14. Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis.
Pinover WH; Hanlon A; Lee WR; Kaplan EJ; Hanks GE
Cancer; 1996 Apr; 77(7):1334-41. PubMed ID: 8608512
[TBL] [Abstract][Full Text] [Related]
15. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
[TBL] [Abstract][Full Text] [Related]
16. Predictors of prostate cancer specific mortality after radical prostatectomy: 10 year oncologic outcomes from the Victorian Radical Prostatectomy Registry.
Bolton DM; Papa N; Ta AD; Millar J; Davidson AJ; Pedersen J; Syme R; Patel MI; Giles GG
BJU Int; 2015 Oct; 116 Suppl 3():66-72. PubMed ID: 26176738
[TBL] [Abstract][Full Text] [Related]
17. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.
Tendulkar RD; Reddy CA; Stephans KL; Ciezki JP; Klein EA; Mahadevan A; Kupelian PA
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1397-404. PubMed ID: 21665379
[TBL] [Abstract][Full Text] [Related]
18. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum prostate-specific antigen and Gleason grade as predictors of pathologic stage in clinically organ confined prostate cancer: implications for the choice of primary treatment.
Ennis RD; Flynn SD; Fischer DB; Peschel RE
Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):317-22. PubMed ID: 7523342
[TBL] [Abstract][Full Text] [Related]
20. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
Rodrigues NA; Chen MH; Catalona WJ; Roehl KA; Richie JP; D'Amico AV
Cancer; 2006 Aug; 107(3):514-20. PubMed ID: 16795068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]